Glenmark Pharmaceuticals has informed that the company has enclosed a press release titled, ‘Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial’.
The above information is a part of company’s filings submitted to BSE.